<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568086</url>
  </required_header>
  <id_info>
    <org_study_id>AFF005B</org_study_id>
    <nct_id>NCT01568086</nct_id>
  </id_info>
  <brief_title>Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005A</brief_title>
  <official_title>Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD03 Applied During AFFiRiS 005A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiris AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiris AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ib follow-up study to evaluate long-term safety and tolerability of
      immunization with AFFITOPE AD03 applied during AFFiRiS 005A.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study could not be performed as planned for organizational reasons.
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/Tolerability</measure>
    <time_frame>52 weeks</time_frame>
    <description>Withdrawal criteria (continuation decision) Number of patients who withdraw due to AEs Reason for withdrawal
Number and kind (description) of AEs
Number and kind (description) of SAEs
Changes from study AFF005A in: Physical and neurological examination/ Concomitant medication/ Vital signs (blood pressure, heart rate, respiratory rate, body temperature)/ Body mass (weight)/ MRI of the brain/ ECG/ Laboratory assessment (haematology, biochemistry, coagulation, serology, APP crossreactivity and urinalysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>52 weeks</time_frame>
    <description>Changes from study AFF005A in:
CIBIC plus (Clinician's Interview-Based Impression of Change, + carer interview)
ADAScog (Alzheimer Disease Assessment Scale-cognitive)
CERAD plus (The Consortium to Establish a Registry for AD)
Neuropsychiatric inventory
Activity of daily living
Quality of life in patients with Alzheimer's disease
Investigator's global evaluation scale
MRI brain volumetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological</measure>
    <time_frame>52 weeks</time_frame>
    <description>- Titre of antibodies specific for the immunizing peptide, N-terminal part of Aβ, Aβ itself, N-terminally truncated and Pyroglutamate-modified versions of Aβ, and KLH by ELlSA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">16</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AFFITOPE AD03 with adjuvant</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>AFFITOPE AD03 without adjuvant</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mild to moderate Alzheimer's disease (MMSE 16 to 26)that have participated in
        AFF005A
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent signed and dated by the patient and the caregiver.

          -  Patients having participated in AFFiRiS 005A and received ≥1 vaccination with AFFITOPE
             AD03

          -  Availability of a partner/caregiver knowing the patient and being able to accompany
             the patient to the visits and being available for the telephone phone calls

        Exclusion Criteria:

          -  Patients having received no vaccination with AFFITOPE AD03

          -  History of questionable compliance to visit schedule; patients not expected to
             complete the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siegfried Kasper, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna ,Department for Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dieter Volc, Prim. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Studienzentrum der PROSENEX,AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Studienzentrum der PROSENEX, AmbulatoriumbetriebsgesmbH an derConfraternität-Privatklinik Josefstadt</name>
      <address>
        <city>Vienna</city>
        <zip>1080</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna, Department for Psychiatry and Psychotherapy</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

